

Mapping the human genetic architecture of COVID-19: an update

COVID-19 Host Genetics Initiative

Author list: <https://docs.google.com/spreadsheets/d/1cp9pFeFUxXz5WMjRFv4X-AM1Hlc0iXYJa1rorSSj2Dc/edit?usp=sharing>


1 Abstract

2 The Coronavirus Disease 2019 (COVID-19) pandemic continues to pose a major public health
3 threat especially in countries with low vaccination rates. To better understand the biological
4 underpinnings of SARS-CoV-2 infection and COVID-19 severity we formed the COVID19 Host
5 Genetics Initiative. Here we present GWAS meta-analysis of up to 125,584 cases and over 2.5
6 million controls across 60 studies from 25 countries, adding 10 new genome-wide significant loci
7 to the 13 we previously identified¹. Genes in novel loci include *SFTPD*, *MUC5B* and *ACE2*,
8 reveal compelling insights regarding disease susceptibility and severity.

9

10 Main text

11 The Coronavirus Disease 2019 (COVID-19) pandemic continues to pose a major public health
12 threat especially in countries with low vaccination rates. To better understand the biological
13 underpinnings of SARS-CoV-2 infection and COVID-19 severity we formed the COVID19 Host
14 Genetics Initiative. Here we present GWAS meta-analysis of up to 125,584 cases and over 2.5
15 million controls across 60 studies from 25 countries, adding 10 new genome-wide significant loci
16 to the 13 we previously identified¹. Genes in novel loci include *SFTPD*, *MUC5B* and *ACE2*,
17 reveal compelling insights regarding disease susceptibility and severity.



18

19 **Figure 1: Panel A: Geographical overview** of the contributing studies to the COVID-19 HGI and composition by
20 major ancestry groups. Populations are defined as Middle Eastern (MID), South Asian (SAS), East Asian (EAS),
21 African (AFR), Admixed American (AMR), European (EUR). **Panel B. Principal components analysis** highlights the
22 population structure and the sample ancestry of the individuals participating to the COVID-19 HGI.

23


24

25 **Additional genomic regions identified for COVID-19 severity and** 26 **SARS-CoV-2 infection**

27 Here we present meta-analyses bringing together 60 studies from 25 countries (**Figure 1;**
28 **Supplementary Table 1**) for three COVID-19 related phenotypes: (1) individuals critically ill with
29 COVID-19 based on either requiring respiratory support in hospital or who died as a
30 consequence of the disease (9,376 cases - of which 3,197 new in this data release - and
31 1,776,645 controls), (2) cases with moderate or severe COVID-19 defined as those hospitalized
32 due to symptoms associated with the infection (25,027 cases – 11,386 new - and 2,836,272
33 controls), and (3) all cases with reported SARS-CoV-2 infection regardless of symptoms
34 (125,584 cases – 76,022 new - and 2,575,347 controls). An overview of the study design is
35 provided in **Supplementary Figure 1**. We found a total of 23 genome-wide significant loci ($P <$
36 5×10^{-8}) of which 20 loci remain significant after multiple testing corrections ($P < 1.67 \times 10^{-8}$) to
37 account for the number of phenotypes examined (**Figure 2; Supplementary Figure 2;**
38 **Supplementary Table 2**).

39

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



41 **Figure 2 | Genome-wide association results for COVID-19.** A. Top panel shows results of genome-wide
42 association study of hospitalized COVID-19 (n=25,027 cases and n=2,836,272 controls), and bottom panel the
43 results of reported SARS-CoV-2 infection (n=125,584 cases and n=2,575,347 controls). Loci highlighted in yellow
44 (top panel) represent regions associated with severity of COVID-19 manifestation. Loci highlighted in green (bottom
45 panel) are regions associated with susceptibility to SARS-CoV-2 infection. Lead variants for the loci newly identified
46 in this data release are annotated with their respective rsID. B. Results of gene prioritization using different evidence
47 measures of gene annotation. Genes in linkage disequilibrium (LD) region, genes with coding variants and eGenes
48 (fine-mapped cis-eQTL variant PIP > 0.1 in GTEx Lung) are annotated if in LD with a COVID-19 lead variant ($r^2 >$
49 0.6). V2G: Highest gene prioritized by OpenTargetGenetics' V2G score. The * indicates SARS-CoV-2 infection
50 susceptibility and + indicates COVID-19 severity. The transparent loci were reported in the previous freeze (data
51 release 5), and loci in bright blue were identified in the current freeze (data release 6).

52 **Heterogeneity in genetic effects across phenotypes, studies, and** 53 **ancestry groups**

54 Across the genome-wide significant loci, we observed clear patterns of association to the
55 different phenotypes under study. Thus, we developed a two-class Bayesian model for
56 classifying loci based on the patterns of association across the two better-powered phenotypes
57 (COVID-19 hospitalization and SARS-CoV-2 reported infection). Intuitively, loci that are
58 associated to susceptibility will also be associated to severity as to develop COVID-19, SARS-
59 CoV-2 infection needs to first occur. In contrast, those genetic effects that solely modify the
60 course of illness should be associated to severity to illness and not show any association to
61 reported infection except via preferential ascertainment of hospitalized cases in a cohort
62 (**Supplementary Methods**). We identified 16 loci that are substantially more likely (> 99%
63 posterior probability) to impact the risk of COVID-19 hospitalization and 7 loci that clearly
64 influence susceptibility to SARS-CoV-2 infection (**Supplementary Table 3**).

65 We observed that several loci had a significant heterogeneous effect across studies (6/23 loci
66 with P-value for heterogeneity < 2.2×10^{-3} ; **Supplementary Table 2**). Thanks to an increased
67 diversity in our study population (**Supplementary Figure 3**) we were able to explore if such
68 heterogeneity was due to effect differences across continental ancestry groups. Only one locus
69 (FOXP4) showed a significantly different effect across ancestries (P-value heterogeneity < 7×10^{-5} ;
70 **Supplementary Table 4 and Supplementary Figure 4**), though even at this locus all
71 ancestry groups showed a positive effect estimate. This confirms that factors related to
72 between-study heterogeneity (e.g., variable definition of COVID-19 severity due to different
73 thresholds for testing, hospitalization, and patient recruitment) rather than differences across
74 ancestries are a more likely explanation for the observed heterogeneity in the effect sizes
75 across studies.

76 **Biological insights from novel loci**

77 For the 23 genome-wide significant loci, we explored candidate causal genes and performed a
78 phenome-wide association study to better understand their potential biological mechanisms
79 (**Supplementary Table 2,5,6; Supplementary Figure 5**). Several of these loci with prior and
80 direct connections to lung disease and SARS-CoV-2 infection mechanism are highlighted here.

81 Several loci involved in COVID-19 severity implicate lung surfactant biology. A missense variant
82 rs721917:A>G (p.Met31Thr) in *SFTPD* (10q22.3) confers risk for hospitalization (OR [95%
83 confidence interval [CI] = 1.06 [1.04, 1.08]; $P = 1.7 \times 10^{-8}$) and has been previously associated
84 with increased risk of chronic obstructive pulmonary disease² (OR = 1.08; $P = 2.0 \times 10^{-8}$), and
85 decreased lung function³ (FEV1/FVC; $\beta = -0.019$; $P = 2.0 \times 10^{-15}$). *SFTPD* encodes the
86 surfactant protein D (SP-D) that participates in innate immune response, protecting the lungs
87 against inhaled microorganisms. The recombinant fragment of SP-D binds to the S1 spike
88 protein of the SARS-CoV-2 and potentially inhibits binding to ACE2 receptor and SARS-CoV-2
89 infection⁴. Another missense variant rs117169628:G>A (p.Pro256Leu) in *SLC22A31* (16q24.3)
90 also conferring risk for hospitalization (OR [95% CI] = 1.09 [1.06, 1.13]; $P = 2.6 \times 10^{-8}$).
91 *SLC22A31* belongs to the family of solute carrier proteins that facilitate transport across
92 membranes⁵ and is co-regulated with other surfactant proteins⁶.

93 We found a variant rs35705950:G>T located in the promoter of *MUC5B* (11p15.5) to be
94 protective against hospitalization (OR [95% CI] = 0.83 [0.86, 0.93]; $P = 6.5 \times 10^{-9}$). This well-
95 studied promoter variant increases expression of *MUC5B* in lung in GTEx ($P = 6.7 \times 10^{-16}$) and
96 is the strongest known variant associated with *increased* risk of developing idiopathic pulmonary
97 fibrosis (IPF)^{7,8}, but also improves survival in IPF patients carrying this mutation⁹.

98 Finally, we identified rs190509934:T>C, located 69 bp upstream of *ACE2* (Xp22.2) to be
99 associated with decreased susceptibility risk (OR [95% CI] = 0.69 [0.63, 0.75]; $P = 3.6 \times 10^{-18}$).
100 *ACE2* is the SARS-CoV-2 receptor and functionally interacts with *SLC6A19* and *SLC6A20*¹⁰,
101 one of which also showed a significant association with susceptibility (rs73062389:G>A at
102 *SLC6A20*; OR [95% CI] = 1.18 [1.16, 1.20]; $P = 2.5 \times 10^{-74}$). Notably, rs190509934 is 10 times
103 more common in South Asians (MAF = 0.027) than in Europeans (MAF = 0.0024),
104 demonstrating the importance of diversity for variant discovery. Recent results have shown that
105 rs190509934:T>C variant lowers *ACE2* expression, which in turn confers protection from SARS-
106 CoV-2 infection¹¹.

107
108 We applied Mendelian randomization to infer potential causal relationships between COVID-19
109 related phenotypes and their genetically correlated traits (**Supplementary Methods;**
110 **Supplementary Table 8,9; Supplementary Figure 6**). A novel causal association was
111 observed between genetic liability to type II diabetes (T2D) and SARS-CoV-2 reported infection
112 (OR [95% CI] = 1.02 [1.01, 1.03]; $P = 1.6 \times 10^{-3}$), and COVID-19 hospitalization (OR [95% CI] =
113 1.06 [1.03, 1.1]; $P = 1.4 \times 10^{-4}$). Multivariable MR (MVMR) was used to estimate the direct
114 effect of liability to T2D on COVID-19-related phenotypes that was not mediated via BMI. This
115 analysis indicated that the observed causal association of liability to T2D on COVID-19
116 phenotypes is mediated by BMI (**Supplementary Table 10**).

117
118

119 Discussion

120

121 We have substantially expanded the genetic analysis of SARS-CoV-2 infection and COVID-19
122 severity by doubling the sample size, identifying 10 novel loci. We developed a new approach to

123 systematically assign the 23 discovered loci to either disease susceptibility (7 loci) or disease
124 severity (16 loci). While distinguishing the two phenotypes is challenging because progression
125 to a severe form of the disease requires susceptibility to infection in the first place, it is now
126 evident that the genetic mechanisms involved in these two aspects of the disease can be
127 differentiated. Among the new loci associated with disease susceptibility, *ACE2* represents an
128 expected, yet interesting finding. *MUC5B*, *SFTPD*, and *SLC22A31* are the three most
129 interesting novel loci associated with COVID-19 severity. Their relationship with lung function
130 and lung diseases is consistent with loci previously associated with disease severity. The SPs
131 secreted by alveolar cells, representing an emerging biological mechanism, maintains healthy
132 lung function and facilitates the clearance of pathogens¹². The protective effect of the *MUC5B*
133 variant is unexpected given the otherwise risk-increasing, concordant effect between IPF and
134 COVID-19 observed for other variants⁸. Nonetheless, this result aligns with the *MUC5B*
135 promoter variant association that shows a twofold higher survival rate among IPF patients⁹. In
136 mice, *Muc5b* appears essential for effective mucociliary clearance and for controlling infection¹³
137 supporting therapies to control mucin secretion to be of potential benefit in COVID-19 patients.
138

139 Expanding genomic research to include participants from around the world enabled us to test if
140 the effect of COVID-19 related genetic variants was markedly different across ancestry groups.
141 This was not the case, and we attribute the observed heterogeneity in the effect of COVID-19
142 related genetic variants to the diverse inclusion criteria across studies in terms of COVID-19
143 severity.
144

145 The novel biological insights gained by this expansion of the COVID-19 Host Genetic Initiative
146 showed that increasing sample size and diversity remain a fruitful activity to better understand
147 the human genetic architecture of COVID-19.
148

149 **References**

- 150
151 1. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19.
152 *Nature* (2021). doi:10.1038/s41586-021-03767-x
- 153 2. Hobbs, B. D. *et al.* Genetic loci associated with chronic obstructive pulmonary disease
154 overlap with loci for lung function and pulmonary fibrosis. *Nat. Genet.* **49**, 426–432 (2017).
- 155 3. Shrine, N. *et al.* New genetic signals for lung function highlight pathways and chronic
156 obstructive pulmonary disease associations across multiple ancestries. *Nat. Genet.* **51**,
157 481–493 (2019).
- 158 4. Hsieh, M.-H. *et al.* Human Surfactant Protein D Binds Spike Protein and Acts as an Entry
159 Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles. *Front. Immunol.* **12**, 641360 (2021).
- 160 5. Hediger, M. A. *et al.* The ABCs of solute carriers: physiological, pathological and
161 therapeutic implications of human membrane transport proteinsIntroduction. *Pflugers Arch.*
162 **447**, 465–468 (2004).
- 163 6. Deelen, P. *et al.* Improving the diagnostic yield of exome- sequencing by predicting gene-
164 phenotype associations using large-scale gene expression analysis. *Nat. Commun.* **10**,
165 2837 (2019).

- 166 7. Seibold, M. A. *et al.* A common MUC5B promoter polymorphism and pulmonary fibrosis. *N.*
167 *Engl. J. Med.* **364**, 1503–1512 (2011).
- 168 8. Fadista, J. *et al.* Shared genetic etiology between idiopathic pulmonary fibrosis and COVID-
169 19 severity. *EBioMedicine* **65**, 103277 (2021).
- 170 9. Peljto, A. L. *et al.* Association between the MUC5B promoter polymorphism and survival in
171 patients with idiopathic pulmonary fibrosis. *JAMA* **309**, 2232–2239 (2013).
- 172 10. Vuille-Dit-Bille, R. N. *et al.* Human intestine luminal ACE2 and amino acid transporter
173 expression increased by ACE-inhibitors. *Amino Acids* **47**, 693–705 (2014).
- 174 11. Horowitz, J. E. *et al.* Common genetic variants identify targets for COVID-19 and individuals
175 at high risk of severe disease. *medRxiv* (2021). doi:10.1101/2020.12.14.20248176
- 176 12. Wright, J. R. Immunoregulatory functions of surfactant proteins. *Nat. Rev. Immunol.* **5**, 58–
177 68 (2005).
- 178 13. Roy, M. G. *et al.* Muc5b is required for airway defence. *Nature* **505**, 412–416 (2014).
179

Supplementary Methods

Detailed description of methods applied.

Supplementary Figures

Supplementary Figure 1

Analytical summary of the COVID-19 HGI meta-analysis. Using the analytical plan set by the COVID-19 HGI, each individual study runs their analyses and uploads the results to the Initiative, who then runs the meta-analysis. There are three main analyses that each study can contribute summary statistics to: critically ill COVID-19, hospitalized COVID-19 and reported SARS-CoV-2 infection. The phenotypic criteria used to define cases are listed in the dark grey boxes, along with the numbers of cases (N) included in the final all ancestries meta-analysis. Controls were defined in the same way across all three analyses: as everybody that is not a case e.g. population controls (light grey box). Sensitivity analyses, not reported in this Figure, also used mild/asymptomatic COVID-19 cases as controls. Sample number (N) of controls differed between the analyses due to the difference in number of studies contributing data to these.

Supplementary Figure 2

Genome-wide association results for COVID-19 critical illness (Release 6). Results of genome-wide association study of critically ill COVID-19 cases vs population controls (n=9,376 cases and n=1,776,645 controls). Critically ill COVID-19 cases defined as those who required respiratory support in hospital or who were deceased due to the disease.

Supplementary Figure 3

Projection of contributed samples from participating studies into the same PC space. We asked participating studies to perform PC projection using the 1000 Genomes Project and Human Genome Diversity Project as a reference, with a common set of variants. For each panel (except for the reference), colored points correspond to contributed samples from each cohort, whereas gray points correspond to the 1000 Genomes reference samples. Color represents a genetic population that each cohort specified. Since 23andme, genomicsengland100kpg, and MVP only submitted PCA images, we overlaid their submitted transparent images using the same coordinates, instead of directly plotting them.

Supplementary Figure 4

Forest plots for highly heterogeneous loci. Forest plots for 6/23 loci that showed a significant heterogeneous effect across studies. For each of the loci, effect sizes and confidence intervals are reported for each contributing study. Studies are grouped by ancestry, with summary effects reported for each ancestry subgroup. The summary effect size across all studies is also reported in the bottom panel for each locus.

Supplementary Figure 5

LocusZoom plots to visualize the meta-analysis results at the loci passing genome-wide significance. For each genome-wide significant locus in three meta-analyses: meta-analysis of

critical illness, hospitalization, and reported infection, we showed 1) a Manhattan plot of each locus where a color represents a weighted-average r^2 value (see COVID-19 Host Genetics Initiative, 2021) to a lead variant (unadjusted P-values from the two-tailed inverse variance weighted meta-analysis); 2) r^2 values to a lead variant across gnomAD v2 populations, i.e., African/African-American (AFR), Latino/Admixed American (AMR), Ashkenazi Jewish (ASJ), East Asian (EAS), Estonian (EST), Finnish (FIN), Non-Finish Europeans (NFE), North-Western Europeans (NWE), and Southern Europeans (SEU); 3) genes at a locus; and 4) genes prioritized by each gene prioritization metric where a size of circles represents a rank in each metric. Note that the COVID-19 lead variants were chosen across all the meta-analyses (Supplementary Table 2) and were not necessarily a variant with the most significant P-value from each inverse variance weighted meta-analysis.

Supplementary Figure 6

Genetic correlations and Mendelian randomization causal estimates between 38 traits and COVID-19 critical illness, hospitalization, and SARS-CoV-2 reported infection. Larger squares correspond to more significant P-values, with genetic correlations or MR causal estimates significantly different from zero at a $P < 0.05$ shown as a full-sized square. Genetic correlations or causal estimates that are significantly different from zero at a false discovery rate (FDR) of 5% are marked with an asterisk. Two-sided P-values were calculated using LDSC for genetic correlations and Inverse variance weighted analysis for MR.

Supplementary Tables

Supplementary Table 1. Information regarding studies contributing to the consortium. All independent studies that contributed data to at least one of the three main all-ancestries meta-analyses are listed, with more detailed information where available. The COVID-19 HGI analysis plan can be found on the consortium's website <https://www.covid19hg.org>.

Supplementary Table 2. Genome-wide significant results from three COVID-19 phenotype meta-analyses. Loci that reached genome-wide significance ($P < 1.67 \times 10^{-8}$) in at least one of our three inverse-variance weighted meta-analyses of COVID-19 phenotypes (results for each loci listed for all three phenotypes): hospitalization due to COVID-19 ($n=25,027$ cases and $n=2,836,272$ controls), and reported SARS-COV-2 infection ($n=125,584$ cases and $n=2,575,347$ controls). Associations that did not reach significance threshold of $P < 1.67 \times 10^{-8}$ in the particular analysis are colored in grey. Effect allele frequency is the sample size weighted frequency across studies included in each meta-analysis. P-value is reported for meta-analysis variant association with trait (P-value association). Suggested phenotypic impact of each locus is probabilistically assigned as "Disease severity" or "Infection susceptibility", as described in the Supplementary Methods and Supplementary Table 3. Between-study heterogeneity P-values (from a two-tailed Cochran's Q test) are reported only for the analysis corresponding to the suggested phenotype. Genes in linkage disequilibrium (LD) region: Genes that overlap with a genomic range that contains any variants in LD ($r^2 > 0.6$) with each lead variant. A gene with a minimum distance to gene body is bolded. Genes with coding variants: Genes with a loss-of-function or missense variant in LD with a lead variant ($r^2 > 0.6$). eGenes: Genes with a fine-mapped cis-eQTL variant (PIP > 0.1) in GTEx and eQTL catalog that is in LD with a lead variant

($r^2 > 0.6$). V2G: Highest gene prioritized by OpenTargetGenetics' V2G score.

Supplementary Table 3. Probabilistic assignment of variants into disease severity vs infection susceptibility. We report the results of the phenotypic impact assignment for each of the genome-wide significant variants reported in Supplementary Table 2. Beta, standard error and p-values are reported for a restricted meta-analysis of hospitalized COVID19 cases (n cases = 23,988 cases, n controls = 2,834,885) and reported SARS-Cov-2 infection (n=114,516 cases, n=2,138,237 controls), including only studies that only contributed to both analysis. Posterior probabilities are reported, to belong to either a disease severity (prob_SEV) or infection susceptibility model (prob_SEV). The phenotypic impact of each variant is assigned with a probability cut-off of 99%.

Supplementary Table 4. Between-ancestry heterogeneity test for COVID-19 meta-analysis lead variants. We report lead variant summary information for each locus reported in Supplementary Table 2, with meta-analysis results stratified by genetic ancestry (AFR=African, AMR=Ad-mixed American, EAS= East Asian, EUR=European, MID=Middle Eastern, SAS=South Asian). Meta-analysis P-values reported are unadjusted values from a two-tailed inverse-variance weighted meta-analysis. Between-analysis heterogeneity P-values from a chi-squared test of the Cochran's Q measure of the effect sizes. Effect allele frequency is the sample size weighted frequency across studies included in each meta-analysis. Sample sizes and number of studies for each ancestry are reported in the table.

Supplementary Table 5. eGenes in GTEx v8 or eQTL catalogue. Genes with at least one fine-mapped cis-eQTL variant (PIP > 0.1) that is in LD with a lead variant ($r^2 > 0.6$) in any tissue of GTEx v8 or eQTL catalogue. The r^2 column represents the r^2 value between the COVID-19 lead variant and eQTL variant.

Supplementary Table 6. PheWAS associations for GWAS lead variants in LD ($r^2 > 0.6$) with COVID-19 index variants. We report phenotype associations for variants which are lead variants of their respective phenotype and in LD ($r^2 > 0.6$) with COVID-19 associated SNPs. The associations were retrieved from OpenTargetsGenetics, UK Biobank and FinnGen.

Supplementary Table 7. SNP heritability estimated for three meta-analysis phenotypes. We used LD score regression (LDSC) to estimate SNP heritability from the European-only summary statistics and All ancestries summary statistics, for our three meta-analysis phenotypes. Heritability P-value was calculated from a two-sided z- distribution. All analyses were performed using European panel LD scores.

Supplementary Table 8. Genetic correlation results between complex traits and COVID phenotypes (EUR only). Two-sided P-values were obtained using LD score regression and adjustments for multiple comparisons were made using FDR. Phenotypes surviving FDR are bolded.

Supplementary Table 9. Causal association of complex traits on COVID-19 phenotypes (EUR only). Two-sided P-values for the primary analysis were obtained using a fixed-effects inverse weighted analysis, with multiple comparisons adjusted for using FDR. Two-sided P-values for the sensitivity analyses were obtained using weighted median estimator (WME), weighted mode based estimator (WMBE), MR Egger regression and MR-PRESSO outlier corrected estimates.

Supplementary table 10 A. Direct effects of BMI and type 2 diabetes on risk of SARS-CoV-2 phenotypes using Multivariable Mendelian Randomization. 10B. Test for weak instruments using Sanderson-Windmeijer conditional F-statistics in multivariable MR.

Supplementary Table 11. Study specific acknowledgements and competing interests.